Global X NASDAQ 100 Covered Call ETF vs GeneDx Holdings Corp — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 4.2× GeneDx Holdings Corp's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and GeneDx Holdings Corp for 19 Days on average.
| QYLD | WGS | |
|---|---|---|
Market Cap | $8.49B | $2.02B |
Volume | 2,913,938 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.68 | $167.51 |
52-Week Low | $16.70 | $34.51 |
Typical Hold Time | 51 Days | 19 Days |
Enterprise Value | — | $2.05B |
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains a consistent monthly dividend payout of $0.18, providing an attractive yield for income-focused investors. Technical indicators present a mixed picture with an overall bullish signal from moving averages but bearish momentum from oscillators, while RSI levels suggest potential overbought conditions. Recent news highlights QYLD's role as a covered call ETF generating income through Nasdaq 100 options strategies.
The outlook for QYLD remains focused on income generation rather than capital appreciation, with the covered call strategy capping upside potential during market rallies. Key risks include declining option premiums, principal erosion over time, and tax treatment uncertainties. Investors should weigh the high monthly yield against the trade-off of limited participation in Nasdaq 100 growth, making it suitable for income needs but less ideal for long-term capital growth objectives.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →